Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia A Southeastern Cancer Study Group study
RS Stein, WR Vogler, J Lefante - American journal of clinical …, 1984 - journals.lww.com
Abstract EIGHTY-FIVE PATIENTS RECEIVING CYTOSINE: arabinoside and daunorubicin
as induction therapy of acute myelogenous leukemia were randomly assigned to receive
lithium carbonate 300 mg tid or no lithium. Treatment groups were similar with respect to
age, gender, baseline granulocyte counts, and patients who were febrile at presentation.
Granulocyte nadirs below 100/cu mm were observed in nearly all patients. The duration of
neutropenia was not significantly shorter for patients receiving lithium (23.3 days) than for …
as induction therapy of acute myelogenous leukemia were randomly assigned to receive
lithium carbonate 300 mg tid or no lithium. Treatment groups were similar with respect to
age, gender, baseline granulocyte counts, and patients who were febrile at presentation.
Granulocyte nadirs below 100/cu mm were observed in nearly all patients. The duration of
neutropenia was not significantly shorter for patients receiving lithium (23.3 days) than for …